Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Myriam Labopin

Showing results (111-120 of 443) with videos related to

Pageof 45
Sort By:
Journal of Hematology & Oncology|November 9, 2016
Long-term survival and late events after allogeneic stem cell transplantation from HLA-matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning: a report on behalf of the acute leukemia working party of European group for blood and marrow transplantationAvichai Shimoni, Myriam Labopin, Bipin Savani, et al.
Blood Cancer Journal|May 13, 2021
Measurable residual disease status and outcome of transplant in acute myeloid leukemia in second complete remission: a study by the acute leukemia working party of the EBMTMaria H Gilleece, Avichai Shimoni, Myriam Labopin, et al.
Bone Marrow Transplantation|March 6, 2021
Prognostic factors for neutrophil engraftment after haploidentical cell transplantation with PT-Cy in patients with acute myeloid leukemia in complete remission, on behalf of the ALWP-EBMTAnnalisa Ruggeri, Myriam Labopin, Emanuele Angelucci, et al.
Journal of Hematology & Oncology|September 4, 2016
Matched and mismatched unrelated donor compared to autologous stem cell transplantation for acute myeloid leukemia in first complete remission: a retrospective, propensity score-weighted analysis from the ALWP of the EBMTFrancesco Saraceni, Myriam Labopin, Norbert-Claude Gorin, et al.
Bone Marrow Transplantation|February 24, 2023
Allogeneic stem cell transplantation for patients with acute myeloid leukemia (AML) in second complete remission (CR2) transplanted from unrelated donors with post-transplant cyclophosphamide (PTCy). A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationArnon Nagler, Myriam Labopin, Ryszard Swoboda, et al.
British Journal of Haematology|May 23, 2019
Second allogeneic stem cell transplantation in patients with acute lymphoblastic leukaemia: a study on behalf of the Acute Leukaemia Working Party of the European Society for Blood and Marrow TransplantationArnon Nagler, Myriam Labopin, Bhagirathbhai Dholaria, et al.
American Journal of Hematology|June 13, 2022
Human leukocyte antigen-haploidentical transplantation for relapsed/refractory acute myeloid leukemia: Better leukemia-free survival with bone marrow than with peripheral blood stem cells in patients ≥55 years of ageFrédéric Baron, Myriam Labopin, Johanna Tischer, et al.
Transplantation and Cellular Therapy|June 17, 2022
Impact of the Addition of Antithymocyte Globulin to Post-Transplantation Cyclophosphamide in Haploidentical Transplantation with Peripheral Blood Compared to Post-Transplantation Cyclophosphamide Alone in Acute Myelogenous Leukemia: A Retrospective Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationGiorgia Battipaglia, Myriam Labopin, Didier Blaise, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 17, 2009
Randomized study of early versus late immunization with pneumococcal conjugate vaccine after allogeneic stem cell transplantationCatherine Cordonnier, Myriam Labopin, Virginie Chesnel, et al.
The Lancet. Haematology|December 22, 2015
Outcomes after use of two standard ablative regimens in patients with refractory acute myeloid leukaemia: a retrospective, multicentre, registry analysisArnon Nagler, Bipin N Savani, Myriam Labopin, et al.
Pageof 45

Showing results (111-120 of 443) with videos related to

Sort By:
Pageof 45
Journal of Hematology & Oncology|November 9, 2016
Long-term survival and late events after allogeneic stem cell transplantation from HLA-matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning: a report on behalf of the acute leukemia working party of European group for blood and marrow transplantationAvichai Shimoni, Myriam Labopin, Bipin Savani, et al.
Blood Cancer Journal|May 13, 2021
Measurable residual disease status and outcome of transplant in acute myeloid leukemia in second complete remission: a study by the acute leukemia working party of the EBMTMaria H Gilleece, Avichai Shimoni, Myriam Labopin, et al.
Bone Marrow Transplantation|March 6, 2021
Prognostic factors for neutrophil engraftment after haploidentical cell transplantation with PT-Cy in patients with acute myeloid leukemia in complete remission, on behalf of the ALWP-EBMTAnnalisa Ruggeri, Myriam Labopin, Emanuele Angelucci, et al.
Journal of Hematology & Oncology|September 4, 2016
Matched and mismatched unrelated donor compared to autologous stem cell transplantation for acute myeloid leukemia in first complete remission: a retrospective, propensity score-weighted analysis from the ALWP of the EBMTFrancesco Saraceni, Myriam Labopin, Norbert-Claude Gorin, et al.
Bone Marrow Transplantation|February 24, 2023
Allogeneic stem cell transplantation for patients with acute myeloid leukemia (AML) in second complete remission (CR2) transplanted from unrelated donors with post-transplant cyclophosphamide (PTCy). A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationArnon Nagler, Myriam Labopin, Ryszard Swoboda, et al.
British Journal of Haematology|May 23, 2019
Second allogeneic stem cell transplantation in patients with acute lymphoblastic leukaemia: a study on behalf of the Acute Leukaemia Working Party of the European Society for Blood and Marrow TransplantationArnon Nagler, Myriam Labopin, Bhagirathbhai Dholaria, et al.
American Journal of Hematology|June 13, 2022
Human leukocyte antigen-haploidentical transplantation for relapsed/refractory acute myeloid leukemia: Better leukemia-free survival with bone marrow than with peripheral blood stem cells in patients ≥55 years of ageFrédéric Baron, Myriam Labopin, Johanna Tischer, et al.
Transplantation and Cellular Therapy|June 17, 2022
Impact of the Addition of Antithymocyte Globulin to Post-Transplantation Cyclophosphamide in Haploidentical Transplantation with Peripheral Blood Compared to Post-Transplantation Cyclophosphamide Alone in Acute Myelogenous Leukemia: A Retrospective Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationGiorgia Battipaglia, Myriam Labopin, Didier Blaise, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 17, 2009
Randomized study of early versus late immunization with pneumococcal conjugate vaccine after allogeneic stem cell transplantationCatherine Cordonnier, Myriam Labopin, Virginie Chesnel, et al.
The Lancet. Haematology|December 22, 2015
Outcomes after use of two standard ablative regimens in patients with refractory acute myeloid leukaemia: a retrospective, multicentre, registry analysisArnon Nagler, Bipin N Savani, Myriam Labopin, et al.
Pageof 45